Results
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
- $24.7 million in Lumvoa ™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -
- Elegrobart Biologics License Application (BLA) submission on track for Q1 2027 -
7- VRDN-008 phase 1 data disclosure on track for Q4 2026 -
- VRDN-292, a potential best-in-class TSHR inhibitor, expected to initiate a phase 1 clinical trial in patients in Q4 2026 -
- Cash, cash equivalents, and marketable securities of $955.2 million as of September 30, 2026 -
WALTHAM, Mass. – Nov. 4, 2026—Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026.
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics.
“These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.
We are excited about this early momentum and look forward to building on it as we continue to execute our launch strategy and strive to bring Lumvoa to more patients with TED.
8Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027.
6In addition, we look forward to several important milestones for the remainder of this year, including sharing clinical data for VRDN-008, development plans for our FcRn portfolio, and initiating a first-in-human clinical trial in patients for our TSHR program VRDN-292.”
5Lumvoa: strong first quarter of launch, as of September 30, 2026:
Lumvoa generated $24.7 million in net product revenue;
More than 100 patients on therapy with Lumvoa;
Significant market access progress made during the quarter;
CMS has assigned Lumvoa a permanent J-code J3242, effective January 1, 2027; and
Continued execution across field sales, medical, market access, and patient services to drive Lumvoa adoption.
Elegrobart: BLA submission on track for Q1 2027
Viridian expects to submit a BLA to the U.S. FDA for elegrobart in TED in Q1 2027.
Viridian anticipates launching elegrobart, if approved, in a commercially available autoinjector with at-home, subcutaneous Q4W and Q8W dosing.
The Lumvoa Commercial and Medical infrastructure is expected to support a potential elegrobart launch with limited incremental investment.
TSHR PROGRAM
VRDN-292: IND on track to initiate a phase 1 clinical trial in patients in Q4 2026
VRDN-292 IND on track to support phase 1 clinical trial initiation in Q4 2026, starting in patients with Graves’ disease.
VRDN-292 is a potential best-in-class, half-life extended, monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR), designed for subcutaneous delivery in an autoinjector with the potential to support extended dosing intervals for patient convenience.
FCRN PORTFOLIO
VRDN-006: VRDN-006 is an Fc fragment that inhibits the neonatal Fc receptor (FcRn).
4In a phase 1 healthy volunteer clinical trial, VRDN-006 showed IgG reductions consistent with the FcRn inhibitor class, spared albumin and LDL, and was generally well-tolerated.
VRDN-008: VRDN-008 is a bispecific, half-life extended FcRn inhibitor.
2In non-human primates, a single, high-dose of VRDN-008 showed a longer half-life and more sustained IgG reduction versus efgartigimod in a head-to-head study.
FcRn update on track for Q4 2026: Viridian expects to announce VRDN-008 phase 1 healthy volunteer data and development plans for the FcRn portfolio in Q4 2026.
Financial Results
Cash Position: Cash, cash equivalents, and marketable securities were $955.2 million as of September 30, 2026.
Existing cash and anticipated future commercial revenues from Lumvoa and elegrobart, if approved, are expected to be able to fund Viridian’s current business plans through profitability.
Net Product Revenue: Net product revenue for Lumvoa was $24.7 million during the three months ended September 30, 2026.
Viridian did not record net product revenue for the same period in 2025.
1R&D Expenses: Research and development expenses were $70.1 million during the three months ended September 30, 2026, compared to $86.3 million during the three months ended September 30, 2025.
The decrease in research and development expenses was driven by reduced expenses related to veligrotug and elegrobart clinical studies, partially offset by additional investment in advancing our TSHR program and FcRn portfolio, as well as increased personnel-related costs as a result of headcount increases.
SG&A Expenses: Selling, general and administrative expenses for the three months ended September 30, 2026 were $57.6 million, compared with $24.3 million for the three months ended September 30, 2025.
The increase in selling, general and administrative expenses was driven by increased personnel-related costs and professional services to support commercial activities for Lumvoa and our growing organization.
3Net Loss: Net loss for the three months ended September 30, 2026 was $101.2 million, compared with $34.6 million for the same period in 2025.
Shares Outstanding: As of September 30, 2026, Viridian had 125,636,093 shares of common stock outstanding on an as-converted basis, which included 113,525,222 shares of common stock and an aggregate 12,110,871 shares of common stock issuable upon the conversion of 133,191 and 48,463 shares of Series A and Series B preferred stock, respectively.
The conference ID is 599668655.
Viridian will participate in the following upcoming investor conferences.
Jefferies Global Healthcare Conference in London : Fireside chat on November 16, 2026, at 11:30 AM GMT in London, UK
UBS Global Biopharma London Conference : Fireside chat on November 17, 2026, at 4:40 PM GMT in London, UK
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases.
Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.
With an immediate focus in thyroid eye disease (TED), we developed Lumvoa TM , a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease.
We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience.
Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.
Viridian is based in Waltham, Massachusetts.
For more information, please visit www.viridiantherapeutics.com .
Follow Viridian on LinkedIn and X .
These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or other similar terms or expressions that concern our expectations, plans and intentions.
Instead, they are based on our current beliefs, expectations, and assumptions.
TED with Q4W and Q8W dosing; Viridian’s product candidates potentially being best-in-class; Viridian’s expectations regarding the potential commercialization, market size, and market opportunities of veligrotug and elegrobart, if approved; and that Viridian’s cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, will be sufficient to fund its business plans through profitability.
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.